Epiomic Epidemiology Series: Gaucher's Disease Forecast in 9 Major Markets 2015-2025
|出版商||Black Swan Analysis||商品編碼||339844|
|出版日期||內容資訊||英文 42 Pages
|高雪氏症:主要9個國家的市場預測 Epiomic Epidemiology Series: Gaucher's Disease Forecast in 9 Major Markets 2015-2025|
|出版日期: 2015年08月11日||內容資訊: 英文 42 Pages||
高雪氏症 (GD) 是由於GBA遺傳基因的先天性常染色體隱性突變引起的疾病。GBA遺傳因子是與生產酶葡糖腦苷脂酶這個酵素有關的遺傳因子，缺乏這個酵素就會導致葡糖腦苷脂和其他類似的物質積蓄在巨噬細胞和單核細胞（白血球）並沉積在各種器官，包括脾，肝，腎和肺中。等到累積到毒性發作的水準就會帶給各個器官不良影響。
本報告提供全球主要9個國家(美國，法國，德國，義大利，西班牙，英國，巴西，日本，印度) 的高雪氏症發病情形相關分析，提供您疾病概要和目前的患病人數，性別·各年代 (以五歲為區分) 的詳細情況，各地區·各民族趨勢，風險要素，疾病診斷與預後，主要的症狀和併發症，未來性的趨勢預測 (今後10年份) 等資訊，為您概述為以下內容。
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Gaucher's Disease in 9 Major Markets
Gaucher's Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage. This report provides the current prevalent population for GD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for GD include:
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.